347 related articles for article (PubMed ID: 27417128)
21. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
22. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women.
Mello G; Biagioni S; Ottanelli S; Nardini C; Tredici Z; Serena C; Marchi L; Mecacci F
J Matern Fetal Neonatal Med; 2015 Feb; 28(3):276-80. PubMed ID: 24724804
[TBL] [Abstract][Full Text] [Related]
23. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study.
Giménez M; Conget I; Nicolau J; Pericot A; Levy I
Acta Diabetol; 2007 Mar; 44(1):34-7. PubMed ID: 17357884
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
25. Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial.
Mueller-Godeffroy E; Vonthein R; Ludwig-Seibold C; Heidtmann B; Boettcher C; Kramer M; Hessler N; Hilgard D; Lilienthal E; Ziegler A; Wagner VM;
Pediatr Diabetes; 2018 Dec; 19(8):1471-1480. PubMed ID: 30302877
[TBL] [Abstract][Full Text] [Related]
26. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
[TBL] [Abstract][Full Text] [Related]
27. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus.
Opipari-Arrigan L; Fredericks EM; Burkhart N; Dale L; Hodge M; Foster C
Pediatr Diabetes; 2007 Dec; 8(6):377-83. PubMed ID: 18036064
[TBL] [Abstract][Full Text] [Related]
28. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
Pickup JC; Sutton AJ
Diabet Med; 2008 Jul; 25(7):765-74. PubMed ID: 18644063
[TBL] [Abstract][Full Text] [Related]
29. Insulin Pumps in Type 1 Diabetes with Mental Disorders: Real-Life Clinical Data Indicate Discrepancies to Recommendations.
Prinz N; Bächle C; Becker M; Berger G; Galler A; Haberland H; Meusers M; Mirza J; Plener PL; von Sengbusch S; Thienelt M; Holl RW;
Diabetes Technol Ther; 2016 Jan; 18(1):34-8. PubMed ID: 26451621
[TBL] [Abstract][Full Text] [Related]
30. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients.
Matejko B; Cyganek K; Katra B; Galicka-Latala D; Grzanka M; Malecki MT; Klupa T
Rev Diabet Stud; 2011; 8(2):254-8. PubMed ID: 22189548
[TBL] [Abstract][Full Text] [Related]
31. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
[TBL] [Abstract][Full Text] [Related]
32. Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment.
Talaviya PA; Saboo BD; Joshi SR; Padhiyar JN; Chandarana HK; Shah SJ; Vyas CK; Shah AN
Diabetes Metab Syndr; 2013; 7(2):68-71. PubMed ID: 23680243
[TBL] [Abstract][Full Text] [Related]
33. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring.
Pettus J; Edelman SV
Diabetes Technol Ther; 2016 Feb; 18 Suppl 2(Suppl 2):S234-42. PubMed ID: 26784128
[TBL] [Abstract][Full Text] [Related]
34. Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET.
Cardona-Hernandez R; Schwandt A; Alkandari H; Bratke H; Chobot A; Coles N; Corathers S; Goksen D; Goss P; Imane Z; Nagl K; O'Riordan SMP; Jefferies C;
Diabetes Care; 2021 May; 44(5):1176-1184. PubMed ID: 33653821
[TBL] [Abstract][Full Text] [Related]
35. Continuous subcutaneous insulin infusion in adult type 1 diabetes mellitus: data from a registry at the University Medical Centre Ljubljana, Slovenia.
Janez A
J Int Med Res; 2012; 40(4):1546-51. PubMed ID: 22971507
[TBL] [Abstract][Full Text] [Related]
36. Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective.
Sumnik Z; Szypowska A; Iotova V; Bratina N; Cherubini V; Forsander G; Jali S; Raposo JF; Stipančic G; Vazeou A; Veeze H; Lange K;
Pediatr Diabetes; 2019 Jun; 20(4):434-443. PubMed ID: 30773756
[TBL] [Abstract][Full Text] [Related]
37. Continuous subcutaneous insulin infusion versus multiple daily injections.
Karagianni P; Sampanis Ch; Katsoulis Ch; Miserlis G; Polyzos S; Zografou I; Stergiopoulos S; Douloumbakas I; Zamboulis Ch
Hippokratia; 2009 Apr; 13(2):93-6. PubMed ID: 19561778
[TBL] [Abstract][Full Text] [Related]
38. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
39. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
Bruttomesso D; Bonomo M; Costa S; Dal Pos M; Di Cianni G; Pellicano F; Vitacolonna E; Dodesini AR; Tonutti L; Lapolla A; Di Benedetto A; Torlone E;
Diabetes Metab; 2011 Nov; 37(5):426-31. PubMed ID: 21474360
[TBL] [Abstract][Full Text] [Related]
40. Three-variate trajectories of metabolic control, body mass index, and insulin dose: Heterogeneous response to initiation of pump therapy in youth with type 1 diabetes.
Tauschmann M; Schwandt A; Prinz N; Becker M; Biester T; Hess M; Holder M; Karges B; Näke A; Kuss O; von Sengbusch S; Holl RW;
Pediatr Diabetes; 2022 May; 23(3):330-340. PubMed ID: 35084795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
